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ABSTRACT 
Cardiorespiratory fitness (CRF) is positively associated with enhanced cardiovascular health. This 
cross-sectional study aimed to determine associations between CRF and the biochemical profile of 
overweight/obese adults diagnosed with primary hypertension (HTN). Does cardiorespiratory fitness 
(exposure) positively affect the biochemical profile (outcome) in overweight/obese individuals 
suffering from HTN? Assessment with anthropometric, ambulatory blood pressure monitoring (24 
hours), CRF (peak oxygen uptake, V̇O2peak), and biochemical analysis was performed on 214 
participants (138 men, 76 women). A series of linear and logistic regression analyses were 
conducted. Participants were divided into CRF tertiles (classified as low, moderate, and high CRF). 
The CRF was independently and inversely associated with aspartate aminotransferase (AST; β=-
0.328, P<0.05) and alanine aminotransferase (ALT; β=-0.376, P<0.01) concentrations. C-reactive 
protein, AST/ALT ratio, gamma-glutamyl transpeptidase, total cholesterol/high-density lipoprotein 
cholesterol ratio, glucose, insulin and insulin resistance index (HOMA-IR), were all associated, but 
not independently, with CRF in linear and/or unadjusted logistic regression models. However, 
independently, logistic regression revealed that glucose was associated with the moderate CRF 
group. Findings suggest that a lower CRF is associated with an unhealthy biochemical profile in non-
physically active and overweight/obese individuals with HTN. As such, this population should look to 
increase physical activity in order to improve their CRF and biochemical profile. 
Keywords: cardiorespiratory fitness; hypertension; overweight; aspartate aminotransferase; alanine 
aminotransferase 
  
 
 
 
 
Introduction 
Primary hypertension (HTN) and overweight/obesity are modifiable cardiovascular (CV) risk factors 
and two of the most common causes of premature death in developed countries [1, 2]. 
Approximately one in three adults have elevated blood pressure (BP), and the body mass index 
(BMI) has dramatically increased in all countries over recent decades [2]. Previously, in patients 
without HTN but overweight/obesity, risk factors such as C-reactive protein (CRP), dyslipidemia, 
insulin resistance and hepatic enzymes have been all associated with metabolic syndrome, type II 
diabetes and CVD [3-5]. In addition, approximately half the population of the Western World has at 
least one lipid abnormality [6]. Further, there is strong evidence to suggest that obesity-related 
disorders such as insulin resistance and type II diabetes are strongly associated with an increased 
risk of HTN [1, 7]. 
Although CVD, HTN, type II diabetes and dyslipidemia are all causes of early morbidity, they 
are cardio-metabolic lifestyle factors that can be altered by adopting healthy lifestyle [2]. 
Cardiorespiratory fitness (CRF) (i.e., aerobic capacity) is positively associated with an enhanced 
cardiovascular health and a reduction in all-cause mortality [8]. Thus, high CRF has been shown to 
suppress the onset of type II diabetes, metabolic syndrome, and CVD in the general population [9, 
10]. More specifically, enhanced CRF has been associated with lower concentrations of CRP in 
overweight men [11], aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in 
overweight women and men [12], as well as higher concentrations of high-density lipoprotein 
cholesterol (HDL-C), and a reduced incidence of hypercholesterolemia adjusted to BMI [13]. 
As such, it could be expected that an enhanced CRF may be positively associated with a 
better biochemical profile in overweight/obese individuals suffering from HTN. Adding to that, in 
order to reduce the obesity epidemic we need to futher enhance our understanding of the 
biochemical profile associated with overweight/obese individuals with HTN. This would allow 
clinicians and research scientists to further understand the complexity surounding the associations 
and causes of CVD. Therefore, the question may be-͞Does Đardiorespiratory fitŶess positiǀely affeĐt 
 
 
 
 
the biochemical profile in overweight/obese individuals suffering from HTN?͟ Thus, the aim of the 
study was to determine associations between CRF and biochemical profile in overweight/obese men 
and women diagnosed with HTN.  
Methods 
Participants 
Two-hundred and fourteen participants (138 men, 76 women) volunteered to participate in the 
EXERDIET-HTA study (Trial Registration: NCT02283047) located in the town of Vitoria-Gasteiz 
(Araba/Álava, Basque Country, Spain) and recruited from the cardiology services and local media. 
Inclusion criteria were having overweight (BMI>25 kg·m-2) or obesity (BMI>30 kg·m-2) [14], and 
diagnosed with HTN, defined as systolic BP (SBP) of 140-179 mmHg and/or diastolic BP (DBP) of 90-
109 mmHg and/or under antihypertensive pharmacological treatment [1]. Physical activity behavior 
was determined by the International Physical Activity Questionnaire (IPAQ), and only participants who 
did not comply with the "Global Recommendations on Physical Activity for Health" by the World Health 
Organization (i.e., at least 150 minutes of moderate-intensity aerobic physical activity throughout the 
week or do at least 75 minutes of vigorous-intensity aerobic physical activity throughout the week or 
an equivalent combination of moderate- and vigorous-intensity activity) were selected [15]. 
All partiĐipaŶts’ demographic data, smoking, and medication data are presented in Table 1. All other 
inclusion and exclusion criteria have been previously published in the study protocol [16]. Study 
design, protocols and informed consent were approved by the ethics committee of the University of 
the Basque Country (UPV/EHU, CEISH/279/2014) and the Ethics Committee of Clinical Investigation 
of Araba University Hospital (2015-030). 
Measurements 
Anthropometry measurements for the assessment of body composition included stature (SECA 213, 
Hamburg, Germany), total body mass (SECA 869, Hamburg, Germany), and BMI. Total body water 
(TBW) and fat mass (FM) were estimated using bioelectrical impedance (Tanita, BF 350, Tokyo, 
 
 
 
 
Japan) according to the general instructions by the manufacture and the theory and fundamentals of 
bioimpedance analysis [17]. An ambulatory BP monitor (ABPM) (6100 Welch Allyn, New York, USA) 
used to determine SBP and DBP at 30 min intervals during the daytime and at 60 min intervals 
during night-time during for a 24 hour period aĐĐordiŶg to report’s reĐoŵŵeŶdatioŶs ďy the 
European Society of Hypertension/European Society Cardiology guidelines [1]. Participants 
previously self-disclosed their typical bedtime and wake up time, and it was used to define the 
assessments per 30 min intervals, and the beginning per 60 min intervals [16]. 
PartiĐipaŶts’ CRF, defined as peak oxygen uptake (V̇O2peak) was assessed on an electronically 
braked Lode Excalibur Sport Cycle Ergometer (Groningen, The Netherlands). Initial power was 40W 
increasing in 10W increments every minute until exhaustion, cadence was maintained at 70 rpm 
throughout. Peak oxygen uptake was determined using a commercially available metabolic cart 
(Ergo CardMedi-soft S.S, Belgium Ref. USM001 V1.0) that was calibrated before each test with a 
standard gas of known concentration and volume. Breath by-breath data were measured 
continuously during exercise and reported in 60-second averages. Achievement of V̇O2peak was 
assumed with the presence of two or more of the following criteria: 1) volitional fatigue (>18 on 
BORG scale), 2) peak respiratory exchange ratio (V̇CO2/V̇O2Ϳ шϭ.ϭ, ϯͿ aĐhieǀiŶg >ϴϱ% of age prediĐted 
maximum heart rate (HR), and 4) failure of V̇O2 and/or HR to increase with further increases in work 
rate [18]. During the test continuous electrocardiogram was monitored throughout. Blood pressure 
was assessed every two minutes (Lode Excalibur automated BP module), and self-reported Borg 
scale (6 to 20 scale) was recorded at the end of each stage. After completion of the test, participants 
remained on the bike five minutes of passive recovery with electrocardiogram and BP monitoring. 
In a separate visit, a blood sample (12.5 mL) was collected from each participant at the Clinical 
Trials Unit of Tecnalia (HUA, Vitoria-Gasteiz) following an overnight fast. That sample was used to 
determine the biochemical profile which consisted of CRP, AST, ALT, gamma-glutamyl 
transpeptidase (GGT), total cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), 
triglycerides (TG), glucose, insulin, and haemoglobin A1c (HbA1c). The AST/ALT and TC/HDL-C ratios 
 
 
 
 
were calculated, and insulin resistance index (HOMA-IR) was determined by [fasting serum insulin 
(µU/mL) x fasting plasma glucose (mg/dL)/405] [19]. 
Cut points of parameters 
According to previous research, concentrations of CRP>3 mg/L indicated cardiometabolic 
abnormality [20]. According to prior study [12], abnormal values for the three hepatic enzymes were 
considered when: >30 U/L for AST, >30 U/L for ALT, >50 U/L for GGT and <1 for AST/ALT ratio. With 
respect to the lipid profile, the Adult Treatment Panel III considers that the concentrations were not 
optimal when different parameters were: TC>200 mg/dL (5.172 mmol/L), LDL-C>100 mg/dL (2.586 
mmol/L), HDL-C<40 mg/dL (1.034 mmol/L), TG>200 mg/dL (2.258 mmol/L) and TC/HDL-C ratio>3.5 
[5]. Based on the Diabetes Federation Statement [21], glucose was considered high when its 
concentration was greater than 100 mg/dL (5.55 mmol/L). The HOMA-IR ratio cut point was 
established at 3.8, insulin cut point at 16.7 mU/L and HbA1c at 6% [22, 23]. 
Statistical analysis 
Data are presented as mean±standard deviation (SD) for continuous variables and percentage (%) 
for categorical variables. For sex comparisons, independent t-tests were used to check mean 
differences for continuous variables, and the chi-square tests were used to verify frequency 
differences for categorical variables. Linear regression was performed to assess the association of 
CRF (independent variable) with the biomarkers (dependent variables) with and without adjustment 
for covariates. The biomarkers CRP, AST, ALT, AST/ALT ratio and GGT were adjusted in model 2 for 
age, sex, FM, TBW, SBP, TC, HDL-C, TG, glucose, insulin, statin intake, hypoglycaemic intake, 
antihypertensive medication intake and smoking status. The lipid profile variables (i.e., CT, HDL, LDL 
TG and CT/HDL) were adjusted as in the previous model 2 excluding the adjustment for TC, HDL-C, 
and TG. Finally, covariates in model 2 for glucose, insulin, HOMA-IR, and % HbA1c were the same of 
the first explained model 2 excluding glucose and insulin. The adjustment of model 3 for all the 
aforementioned variables included all covariates of model 2 plus BMI. Odds ratios (ORs) and 95% 
confidence intervals (95% CI) were estimated (with and without adjustment for covariates) using 
 
 
 
 
logistic regression models to evaluate the associations of CRF with the relevant biomarkers, taking 
into account the previously explained cut points. Participants were mathematically divided into CRF 
tertiles (i.e., low, moderate and high CRF) for logistic regression analysis. The range in each group 
were as follows; the lowest tertile (Low-CRF group): V̇O2peakчϮϭ.ϵ ŵL·kg-1·min-1 in men and 
V̇O2peakчϭϳ.Ϯ ŵL·kg- 1·min-1 in women; the medium tertile (Moderate-CRF group): 21.9<V̇O2peakчϮϲ.ϱ 
mL·kg-1·min-1 in men and 17.2<V̇O2peakчϮϭ.ϭ ŵL·kg-1·min-1 in women; the highest tertile (High-CRF 
group): V̇O2peak>26.5 in men and V̇O2peak>21.1 mL·kg-1·min-1 in women. Statistical significance was set 
at P<0.05. All analyses were performed using Statistical Package for Social Sciences (IBM, Version 
24). 
Results 
When split by sex (Table 1), men presented a higher (P<0.05) age, TBW, DBP, V̇O2peak, AST, ALT and 
TG, whilst women showed a higher (P<0.05) FM, TC, HDL-C and LDL-C concentrations. There were no 
significant sex differences in any other variables.  
 
Table 1. Demographic and descriptive characteristics of the participants split by sex. Values are 
meanSD or percentages (%) for categorical variables. 
  All (N=214) Men (N=138) Women (N=76) P 
Age (years) 53.5±7.7 54.4±7.9 52.0±7.3 0.03* 
BMI (Kg/m2) 32.0±4.5 31.9±4.2 32.0±5.0 0.9 
TBW (%) 48.4±6.5 50.7±4.6 44.3±7.2 <0.001*** 
FM (%) 34.3±8.5 30.8±7.7 40.8±5.7 <0.001*** 
SBP (mmHg) 136.2±12.8 136.8±12.2 135.2±14.0 0.4 
DBP(mmHg) 78.4±8.3 79.7±7.6 76.1±8.9 0.003** 
V̇O2peak (mL·kg-1·min-1) 22.5±5.4 24.1±5.3 19.6±4.4 <0.001*** 
CRP (mg/L) 4.3±4.3 3.8±4.0 5.0±4.6 0.1 
AST (U/L) 25.3±11.6 26.8±12.7 22.4±8.6 0.01* 
ALT (U/L) 32.2±20.9 35.3±22.1 26.6±17.4 0.002** 
AST/ALT 0.90±0.4 0.86±0.49 0.98±0.3 0.08 
GGT (U/L) 39.1±43.3 43.0±48.4 29.5±25.2 0.1 
TC (mmol/L) 5.3±0.9 5.2±1.0 5.6±0.9 0.007** 
HDL-C (mmol/L) 1.2±0.3 1.2±0.2 1.4±0.3 <0.001*** 
LDL-C (mmol/L) 3.4±0.8 3.3±0.9 3.6±0.8 0.02* 
TG (mmol/L) 1.6±0.9 1.7±1.0 1.3±0.6 0.003** 
 
 
 
 
TC/HDL-C 4.5±1.5 4.6±1.6 4.2±1.1 0.05  
Glucose (mmol/L) 5.7±1.4 5.6±1.2 5.8±1.6 0.4  
Insulin (mU/L) 12.0±7.3 11.8±7.6 12.4±6.8 0.7  
HOMA-IR 3.3 ±2.6 3.1±2.3 3.5±3.0 0.4 
HbA1c (%) 6.0±0.9 5.9±0.9 6.0±0.9 0.7 
Statin (%) 14 15.9 10.5 0.3 
Hypoglycemic (%) 7 9.4 2.6 0.1 
ACEI (%) 36.9 35.5 39.5 0.6 
ARB (%) 43 44.2 40.8 0.6 
Diuretic (%) 40.2 37.7 44.7 0.3 
CCB (%) 15 18.1 9.2 0.1 
BB (%) 7.5 7.2 7.9 0.9 
Antiplatelet (%) 4.7 5.8 2.6 0.3 
Smokers (%) 12.1 13 10.5 0.6 
BMI: Body mass index. TBW: Total body water. FM: Fat mass. SBP: Systolic blood pressure. DBP: Diastolic 
blood pressure. V̇O2peak: Peak oxygen consumption. CRP: C reactive protein. AST: Aspartate 
aminotransferase. ALT: Alanine transaminase. GGT: Gamma-glutamyl transpeptidase. TC: Total cholesterol. 
HDL-C: High-density lipoprotein cholesterol. LDL-C: Low-density lipoprotein cholesterol. TG: Triglycerides. 
HOMA-IR: Insulin resistance index. HbA1c: haemoglobin A1c. SD: Standard deviation. ACEI: Angiotensin-
converting-enzyme inhibitors. ARB: Angiotensin II receptor blockers. CCB: Calcium channel blockers. BB: 
Beta-blockers.  
Significant difference between men (M) and women (W): *P<0.05, **P<0.01, ***P<0.001 
 
A series of linear regression analyses were conducted to assess the independent associations 
between V̇O2peak and variables in the biochemical profile. As shown in Table 2, V̇O2peak was negatively 
associated with CRP (P<0.001) unadjusted, however, but no significant associations in models 2 and 
3 (P=0.084). V̇O2peak was negatively associated with ALT both unadjusted (P=0.007) and following 
adjustment of covariates (P=0.005). Whilst AST was not significantly associated without adjustment, 
it was significantly associated when covariates were considered (P=0.026) in the model β 
Coefficients of model 3 for AST and ALT were -0.328 and -0.376, respectively. The AST/ALT ratio was 
related to V̇O2peak without adjustment ;β=Ϭ.ϭϱϯͿ but not when adjustments in model 2 and 3 were 
made. V̇O2peak was not significantly associated with GGT. No significant associations were found 
between V̇O2peak and any of the lipid profile variables (TC, HDL-C, LDL-C, TG and TC/HDL-C). In 
addition, V̇O2peak was not associated with HbA1c (Table 3).  
  
 
 
 
 
Table 2. Linear regression models. Association between V̇O2peak and CRP and 
hepatic enzymes. N=214. 
Linear regression 
model 
β 
Coefficient 
LCI UCI P Model R2 
V̇O2peak–CRP      
Unadjusted -0.377 -0.568 -0.187 <0.001 0.142 
Model 2 -0.296 -0.638 0.048 0.090 0.212 
Model 3 -0.269 -0.575 0.037 0.084 0.258 
V̇O2peak–AST      
Unadjusted -0.051 0.196 -0.094 0.487 0.003 
Model 2 -0.329 -0.616 -0.042 0.026 0.321 
Model 3 -0.328 -0.616 -0.040 0.026 0.324 
V̇O2peak–ALT      
Unadjusted -0.187 -0.323 -0.051 0.007 0.035 
Model 2 -0.377 -0.635 -0.119 0.005 0.452 
Model 3 -0.376 -0.632 -0.120 0.005 0.466 
V̇O2peak-AST/ALT      
Unadjusted 0.153 0.013 0.306 0.037 0.023 
Model 2 0.131 -0.131 0.393 0.305 0.458 
Model 3 0.128 -0.128 0.384 0.318 0.469 
V̇O2peak–GGT      
Unadjusted -0.128 -0.304 0.048 0.153 0.016 
Model 2 -0.151 -0.548 0.246 0.441 0.644 
Model 3 -0.115 -0.491 0.261 0.534 0.701 
Model 2 covariates: age, sex, fat mass, total body water, systolic blood pressure, 
total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, 
insulin, statin intake, hypoglycemic intake, antihypertensive medication intake, 
smoking status. Model 3: model 2 + body mass index. V̇O2peak: Peak oxygen 
consumption. CRP: C reactive protein. AST: Aspartate aminotransferase. ALT: 
Alanine transaminase. GGT: Gamma-glutamyl transpeptidase. LCI: Lower 
confidence interval (95%). UCI: Upper confidence interval (95%). 
 
Table 3. Linear regression models. Association between V̇O2peak and lipid profile and insulin 
sensitivity. N=214. 
Linear regression 
model 
β Coefficient LCI UCI P Model R2 
V̇O2peak-TC      
Unadjusted -0.002 -0.162 0.158 0.981 0.000 
Model 2 0.129 -0.171 0.429 0.394 0.164 
Model 3 0.123 -0.177 0.423 0.413 0.184 
V̇O2peak–HDL-C      
Unadjusted -0.050 -0.188 0.088 0.473 0.002 
Model 2 0.180 -0.102 0.462 0.209 0.262 
Model 3 0.173 -0.108 0.454 0.223 0.282 
 
 
 
 
V̇O2peak–LDL-C      
Unadjusted 0.054 -0.087 0.195 0.452 0.003 
Model 2 0.235 -0.064 0.534 0.121 0.271 
Model 3 0.226 -0.074 0.526 0.137 0.279 
V̇O2peak-TG      
Unadjusted 0.022 -0.179 0.093 0.748 0.000 
Model 2 0.063 -0.237 0.363 0.677 0.193 
Model 3 0.066 -0.232 0.364 0.661 0.197 
V̇O2peak-TC/HDL      
Unadjusted 0.040 -0.096 0.176 0.563 0.002 
Model 2 -0.131 -0.427 0.165 0.377 0.201 
Model 3 -0.131 -0.427 0.165 0.382 0.201 
V̇O2peak-Glucose      
Unadjusted -0.163 -0.297 -0.029 0.017 0.027 
Model 2 -0.088 -0.239 0.063 0.253 0.221 
Model 3 -0.057 -0.215 0.101 0.478 0.229 
V̇O2peak-Insulin      
Unadjusted -0.244 -0.454 -0.035 0.023 0.059 
Model 2 -0.247 -0.503 0.009 0.059 0.389 
Model 3 -0.198 -0.438 0.042 0.104 0.486 
V̇O2peak-HOMA-IR      
Unadjusted -0.288 -0.494 -0.082 0.007 0.083 
Model 2 -0.258 -0.527 0.011 0.060 0.332 
Model 3 -0.208 -0.463 0.045 0.106 0.428 
V̇O2peak-% HbA1c      
Unadjusted -0.149 -0.354 0.062 0.166 0.022 
Model 2 -0.080 -0.302 0.142 0.486 0.438 
Model 3 -0.042 -0.246 0.168 0.703 0.501 
Model 2 covariates for TC, HDL-C, LDL-C, TG and TC/HDL-C: age, sex, fat mass, total body 
water, systolic blood pressure, glucose, insulin, statin intake, hypoglycemic intake, 
antihypertensive medication intake, smoking status. Model 3 for TC, HDL-C, LDL-C, TG and 
TC/HDL-C: model 2 + body mass index. Model 2 covariates for glucose, insulin, HOMA-IR 
and % HbA1c: age, sex, fat mass, total body water, systolic blood pressure, TC, HDL-C, TG, 
statin intake, hypoglycemic intake, antihypertensive medication intake, smoking status. 
Model 3 for glucose, insulin, HOMA-IR and % HbA1c: model 2 + body mass index. V̇O2peak: 
Peak oxygen consumption. TC: Total cholesterol. HDL-C: High density lipoprotein 
cholesterol. LDL-C: Low density lipoprotein cholesterol. TG: Triglycerides. HOMA-IR: Insulin 
resistance index. HbA1c: haemoglobin A1c. LCI: Lower confidence interval (95%). UCI: 
Upper confidence interval (95%). 
 
 
 
 
 
However, when the regression was conducted without any adjustment, a negative 
relationship was found between V̇O2peak and glucose, insulin and HOMA-IR (β=-Ϭ.ϭϲϯ, β=-0.244 and 
β=-0.288, respectively). But the association was not significant following adjustment (P>0.05). 
For some independent variables, logistic regression analysis confirmed the linear regression 
models. As shown in Table 4, high CRF group was 87% less likely to have elevated CRP when 
unadjusted. The association was significant in model 2 (high CRF group was 83% less likely to have 
elevated CRP), however, in model 3, only a trend toward significance was shown (P<0.064). 
Otherwise, moderate and high CRF groups were less likely to have elevated AST (98% and 96%, 
respectively) and elevated ALT (87% and 89%, respectively) in model 3. GGT was associated with CRF 
groups in unadjusted analysis (i.e., 71% and 80% less likely to have elevated GGT in moderate and 
high CRF groups, respectively). However, no significant association (P>0.05) was found following 
adjustment for covariates (Table 4). 
 
 
 
 
Table 4. Logistic regression models. Association between V̇O2peak and CRP and hepatic enzymes. N=214.  
    Unadjusted   Model 2   Model 3 
    OR LCI UCI P   OR LCI UCI P   OR LCI UCI P 
Elevated CRP                
Moderate CRF  0.588 0.217 1.594 0.297 
 1.158 0.274 4.894 0.842  1.119 0.267 4.678 0.878 
High CRF  0.128 0.037 0.443 0.001 
 0.173 0.031 0.965 0.045  0.194 0.034 1.102 0.064 
Elevated AST                
Moderate CRF  0.416 0.176 0.982 0.045 
 0.022 0.002 0.288 0.004  0.023 0.002 0.288 0.004 
High CRF  0.186 0.059 0.587 0.004 
 0.040 0.003 0.619 0.021  0.041 0.003 0.641 0.023 
Elevated ALT  
     
         
Moderate CRF  0.456 0.231 0.900 0.024 
 0.145 0.032 0.650 0.012  0.127 0.026 0.62 0.011 
High CRF  0.221 0.103 0.474 <0.001 
 0.121 0.019 0.768 0.025  0.109 0.016 0.75 0.024 
Low AST/ALT                
Moderate CRF  1.836 0.769 4.385 0.171  0.336 0.041 2.769 0.310  0.310 0.035 2.718 0.290 
High CRF  2.627 1.091 6.327 0.153  0.229 0.019 2.712 0.243  0.225 0.019 2.678 0.238 
Elevated GGT                
Moderate CRF  0.293 0.095 0.901 0.032 
 0.009 0.000 4.216 0.133  0.009 0.000 4.978 0.145 
High CRF   0.202 0.053 0.768 0.019   25.965 0.060 11299.629 0.293   25.832 0.062 10691.539 0.290 
These odds ratios are referring for that in the low CRF group. Model 2 covariates: age, sex, fat mass, total body water, 
systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, insulin, statin 
intake, hypoglycemic intake, antihypertensive medication intake, smoking status. Model 3: model 2 + body mass index. 
CRP: C reactive protein. AST: Aspartate aminotransferase. ALT: Alanine transaminase. GGT: Gamma-glutamyl 
transpeptidase. OR: Odds ratio. LCI: Lower confidence interval (95%). UCI: Upper confidence interval (95%). 
 
 
 
 
 
 
Logistic regression did not show a significant association between CRF groups and elevated TC, 
HDL-C, LDL-C, and TG (Table 5). The high CRF group was 62% less likely to have an elevated TC/HDL-C 
ratio when compared to the low CRF group, but there was no significant association following 
adjustment. For glucose, associations were found in moderate and high CRF groups when 
unadjusted and following adjustment for covariates in model 2 (P=0.014 and P=0.046 for moderate 
and high CRF groups, respectively). In model 3, the moderate CRF group was 64% less likely to have 
elevated glucose compared to the low CRF group (P=0.016), but there was no significance in high 
CRF group (P=0.096). HOMA-IR showed a significant association with the high CRF group in the 
unadjusted model (P=0.037) and in model 2 (P=0.043). However, but there was no significance in 
model 3 (P=0.062). Using logistic regression insulin and HbA1c did not show any significant 
associations with the CRF groups (Table 5).
 
 
 
 
Table 5. Logistic regression models. Association between V̇O2peak and lipid profile and insulin sensitivity. N=214. 
    Unadjusted   Model 2   Model 3 
    OR LCI UCI P   OR LCI UCI P   OR LCI UCI P 
Elevated TC                
Moderate CRF  1.027 0.535 1.970 0.936 
 0.315 0.070 1.423 0.133  0.317 0.071 1.419 0.133 
High CRF  1.528 0.780 2.995 0.217 
 2.224 0.373 13.260 0.380  2.207 0.373 13.067 0.383 
Low HDL-C                
Moderate CRF  0.867 0.394 1.905 0.722 
 2.521 0.459 13.837 0.287  2.243 0.402 12.503 0.357 
High CRF  0.636 0.273 1.479 0.293 
 0.557 0.067 4.602 0.587  0.511 0.060 4.358 0.539 
Elevated LDL-C  
     
         
Moderate CRF  0.546 0.218 1.367 0.196 
 0.349 0.026 4.666 0.454  0.358 0.027 4.818 0.439 
High CRF  1.200 0.419 3.439 0.734 
 1.605 0.056 46.155 0.873  1.606 0.057 45.426 0.781 
Elevated TG                
Moderate CRF  1.182 0.491 2.847 0.710 
 0.711 0.115 4.378 0.713  0.496 0.072 3.434 0.478 
High CRF  0.626 0.227 1.723 0.364 
 1.347 0.141 12.885 0.796  1.073 0.105 11.016 0.952 
Elevated TC/HDL               
Moderate CRF  0.589 0.260 1.335 0.205 
 0.286 0.045 1.837 0.187  0.278 0.042 1.815 0.181 
High CRF  0.383 0.172 0.851 0.018 
 0.384 0.052 2.852 0.350  0.381 0.051 2.847 0.347 
Elevated Glucose                
Moderate CRF  0.529 0.273 1.025 0.059 
 0.357 0.158 0.809 0.014  0.364 0.160 0.827 0.016 
High CRF  0.388 0.194 0.777 0.008 
 0.408 0.170 0.983 0.046  0.457 0.182 1.148 0.096 
Elevated Insulin  
     
         
Moderate CRF  1.842 0.552 6.140 6.140 
 1.992 0.397 9.990 0.402  2.383 0.420 13.529 0.327 
High CRF  0.126 0.014 1.172 0.069 
 0.058 0.001 2.300 0.129  0.070 0.002 2.563 0.148 
Elevated HOMA-IR              
Moderate CRF  1.161 0.378 3.567 0.795 
 0.605 0.116 3.167 0.552  0.632 0.106 3.771 0.614 
High CRF  0.165 0.030 0.898 0.037 
 0.088 0.008 0.931 0.043  0.109 0.011 1.118 0.062 
Elevated % HbA1c              
Moderate CRF  1.006 0.323 3.134 0.992  1.566 0.362 6.774 0.548  1.797 0.353 9.150 0.481 
High CRF   0.366 0.092 1.453 0.153   0.359 0.050 2.595 0.310   0.464 0.058 3.694 0.469 
 
 
 
 
These odds ratios are referring for that in the low CRF group. Model 2 covariates for TC, HDL-C, LDL-C, TG and TC/HDL-C: 
age, sex, fat mass, total body water, systolic blood pressure, glucose, insulin, statin intake, hypoglycemic intake, 
antihypertensive medication intake, smoking status. Model 3 for TC, HDL-C, LDL-C, TG and TC/HDL-C: model 2 + body 
mass index. Model 2 covariates for glucose, insulin, HOMA-IR and % HbA1c: age, sex, fat mass, total body water, systolic 
blood pressure, TC, HDL-C, TG, statin intake, hypoglycemic intake, antihypertensive medication intake, smoking status. 
Model 3 for glucose, insulin, HOMA-IR and % HbA1c: model 2 + body mass index. TC: Total cholesterol. HDL-C: High 
density lipoprotein cholesterol. LDL-C: Low density lipoprotein cholesterol. TG: Triglycerides. HOMA-IR: Insulin 
resistance index. HbA1c: haemoglobin A1c. OR: Odds ratio. LCI: Lower confidence interval (95%). UCI: Upper confidence 
interval (95%). 
 
 
 
 
 
Discussion 
Although population from this study has been previously categorized by sex and CRF level [24], to 
our knowledge, this is the first study to determine the relationship between CRF and biochemical 
profile in overweight/obese adults diagnosed with HTN. The main findings of the study were: 1) CRF 
was independently and inversely associated with concentrations of AST and ALT; these relationships 
were confirmed by linear and logistic regression analysis. 2) CRP, AST/ALT ratio, GGT, TC/HDL-C ratio, 
glucose, insulin and HOMA-IR, were associated, but not independently, with CRF in unadjusted linear 
and/or logistic regression models. In addition, glucose was independently associated in logistic 
regression analysis, with the moderate CRF group. As such, they were less likely to have elevated 
glucose compared to the low CRF group. A trend was observed in the high CRF group, but this was 
not significant. 
Previously, higher levels of CRF and physical activity were inversely associated with hepatic 
enzymes [12, 25]. In agreement with the current study, previous literature has reported an inverse 
association between CRF and both AST and ALT, which was independent of body composition [12, 
25]. When unadjusted, GGT and AST/ALT ratio showed a favorable association with CRF, but it was 
dependent of other covariates. Other research has described similar findings [26], indicating that 
body composition mediated CRF and its relationship with GGT and AST/ALT. It is known that hepatic 
enzymes are found not only in the liver but also in cardiac and muscle cells. However, while ALT and 
GGT mainly exist in the hepatic cells and, therefore, are related to liver and abdominal fat, AST is 
also present in cardiac and muscle cells. Thus, low CRF arising from the lack of regular aerobic 
exercise has adverse effects on the hepatic enzymes and muscle oxidative capacity, concentrations 
of AST, ALT (i.e., in the present study high CRF group was 96% and 85% less likely to have elevated 
concentrations in model 3, respectively) and GGT (i.e., high CRF group was 80% less likely to have 
raised concentration in model 1) [12]. These results may be associated with the presence of non-
alcoholic fatty liver disease [27]. 
 
 
 
 
Previous studies which did not look at overweight/obese populations with HTN have 
suggested that a high CRF may attenuate the risk of incidence in HTN in individuals with high 
concentrations of inflammatory markers, such as CRP [28]. Thus, better CRF was strongly associated 
with reduced CRP concentrations even after adjustment for BMI and FM [11, 29]. In addition, a 
better body composition has previously been associated with lower CRP concentrations [30], and 
higher CRF with an enhanced body composition [31]. Findings from the current study may support 
the notion that CRF is negatively associated with CRP, even though the adjusted analysis only 
showed a trend toward significance. Thus, it may be that there is an underlying mechanism that 
explains the relationship, although it is still not well understood [29]. Circulating concentrations of 
some inflammatory markers, in particular CRP, raises the risk of development and progression of 
atherosclerosis, and as a consequence are reliable predictors of CV events [32]. Although it is beyond 
the scope of this paper, previous studies have presented the potential pathways: 1) hepatic CRP 
production is stimulated by interleukin-6 and, to a lesser extent, by interleukin-1 and tumor necrosis 
factor-α, ǁhiĐh are stiŵulated from the visceral adipose tissue [11]; 2) regular physical activity and 
acute exercise have shown to decrease resting concentrations of interleukin-6 and tumor necrosis 
factor-α aŶd, thus, poteŶtially, CRP [11, 29]; 3) increased sympathetic stimulation is related to 
inflammation. Therefore, reductions in inflammatory markers occur with an enhanced fitness and 
concomitant better autonomic nervous system activity through exercise-induced cholinergic anti-
inflammatory pathways [33]. 
No associations were found between CRF and any markers of lipid profile in the current 
study with the exception of TC/HDL-C ratio. Those participants with high CRF had reduced chance of 
having a high TC/HDL-C ratio (62% less likely); though, the association disappeared when adjusted. 
The TC/HDL-C ratio is an essential cumulative index of the presence of an atherogenic dyslipidemic 
profile related to insulin resistance [34]. Lack of exercise or low CRF is linked with a greater 
endothelial dysfunction (i.e., reduced vasodilation along with greater proinflammatory and 
prothrombic markers), HTN and an increased TC/HDL-C [35]. However, exercise has been shown to 
 
 
 
 
remodel the vessels positively [35]. Likewise, previous studies found an association between CRF and 
lipid profile, directly with HDL-C and inversely with TG and TC/HDL-C ratio [9, 36], while LDL-C 
appears not to be linked with CRF. A recent longitudinal study has shown that anthropometric 
parameters, such as BMI and waist circumference, were more associated with blood lipids than CRF 
was [36]. Thus, a better anthropometric profile could improve the blood lipid profile, while CRF may 
have limited influence [36]. However, more research is needed to confirm the lack of association 
shown in overweight/obese participants with HTN.  
Indicators of glucose tolerance and insulin resistance (specifically, glucose, insulin, and 
HOMA-IR) were inversely linked with CRF in the current study (Tables 3 and 5), but HbA1c did not 
show any association with CRF. Previously, the association between CRF, glucose tolerance and 
insulin resistance has been apparent, and it appears to be independent of body composition [37, 
38]. In the present study, the glucose concentration also shows an independent association in 
logistic regression analysis with the moderate CRF group (i.e., resulting in less likely to have elevated 
glucose than the low CRF group). However, not all studies showed independence from body 
composition [10], and as such more research is needed to clarify the potential associations between 
these parameters, particularly in an overweight/obese population with HTN. Even so, according to 
previous research, it seems clear that an increased CRF in obese adults has positive effects on insulin 
sensitivity [38].  
Due to the associations among CRF, biochemical profile, CV risk and mortality [4, 8, 32], the 
results of the current study build on evidence of highlighting the usefulness of CRF as a potential 
screening tool in the public health setting. Early identification of low CRF would mean early 
detection of people with higher odds of developing CVD and mortality [8, 13]. The present study 
highlights the importance that CRF has in maintaining a healthy biochemical profile.  
The authors feel that to interpret findings from the current study, it is essential to consider 
the strengths and limitations. The design of the study allowed for a good cross-sectional 
presentation. Although the aim of the study was not to establish mechanisms behind the 
 
 
 
 
relationships, we were able to identify several associations in a small (n=214) but specific population 
with overweight/obesity and HTN. However, possible confounding factors could have influenced the 
relationships, such as physical activity or diet, and even though the analysis was adjusted with 
medications, it is difficult to assess their influence on the results. Despite this, using the objective 
measure of CRF and the inclusion of body composition as a covariate in the analyses, we have 
significantly enhanced the existing body of research in this at-risk population.  
Conclusion 
The current study suggests that CRF is associated with the biochemical profile in an 
overweight/obese population with HTN. An inverse and independent association was observed 
between CRF and AST and ALT, while the influence of CRF is limited by other covariates in the 
association with CRP, AST/ALT ratio, GGT, TC/HDL-C ratio, glucose, insulin, and HOMA-IR. As such, a 
healthy lifestyle intervention should be adopted by this population to improve CRF and consequently 
their biochemical profile. Future work should look to determine the effects of conducting regular 
physical activity and exercise to enhance CRF and biochemical profile. 
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